Your shopping cart is currently empty

Erufosine is an inhibitor of the PI3K/Akt and Ras/Raf/MAPK signaling pathways. It suppresses the activity of breast cancer cell lines MCF-7 and MDA-MB 231 with an IC50 of 40.95/40.8 μM, respectively. Erufosine reduces phosphorylation of PI3K(p85), Akt (PKB), and cRaf, making it applicable in research on breast cancer and myeloid leukemia.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | Erufosine is an inhibitor of the PI3K/Akt and Ras/Raf/MAPK signaling pathways. It suppresses the activity of breast cancer cell lines MCF-7 and MDA-MB 231 with an IC50 of 40.95/40.8 μM, respectively. Erufosine reduces phosphorylation of PI3K(p85), Akt (PKB), and cRaf, making it applicable in research on breast cancer and myeloid leukemia. |
| Synonyms | Erucylphosphohomocholine, ErPC3 |
| Molecular Weight | 503.74 |
| Formula | C28H58NO4P |
| Cas No. | 202867-33-2 |
| Smiles | P(OCCCCCCCCCCCC/C=C\CCCCCCCC)(OCCC[N+](C)(C)C)(=O)[O-] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.